Director Jeffrey Evan Hammerbacher filed an initial statement of beneficial ownership with the SEC on November 19, 2026, disclosing his status as a newly reporting person at Roivant Sciences Ltd. following a triggering event dated November 9, 2026.

Key Highlights

  • Reporting person: Jeffrey Evan Hammerbacher is identified as a Director of Roivant Sciences Ltd.
  • Triggering event date: The date of the event requiring the statement is listed as November 9, 2026.
  • No securities held: The filing states "No securities are beneficially owned" in both Table I (non-derivative securities) and Table II (derivative securities).
  • Filing date: The form was signed and filed on November 19, 2026, by Sam Kaplan as attorney-in-fact for Jeffrey Hammerbacher.
  • Individual filing: The form was filed by one reporting person, not a group.

Hammerbacher Reports Zero Beneficial Ownership on Joining Roivant Board

Jeffrey Evan Hammerbacher submitted a Form 3 - Initial Statement of Beneficial Ownership of Securities - to the United States Securities and Exchange Commission, filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. The issuer is Roivant Sciences Ltd., listed on NASDAQ:ROIV. The filing covers the period beginning with the event date of November 9, 2026, which the form identifies as the date requiring the statement.

According to the filing, Hammerbacher's relationship to the issuer is that of Director. Both Table I, covering non-derivative securities, and Table II, covering derivative securities such as puts, calls, warrants, options, and convertible securities, carry the notation "No securities are beneficially owned." The filing therefore discloses no share counts, prices, ownership forms, or indirect ownership arrangements of any kind.

The form was executed by Sam Kaplan acting as attorney-in-fact for Jeffrey Hammerbacher, with a signature date of November 19, 2026. Hammerbacher's address of record is listed as c/o Roivant Sciences Ltd., 7th Floor, 50 Broadway, London SW1H 0DB, United Kingdom. No amendments to a prior filing are indicated, and no exhibit other than a Power of Attorney (Exhibit 24) is listed.

What Was Disclosed

Roivant Sciences Ltd. Director Jeffrey Evan Hammerbacher filed an initial beneficial ownership statement reporting no holdings of any securities, derivative or otherwise, in the company as of the November 9, 2026 event date.